Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals PLC is a company that develops drug delivery technologies. The company was originally formed as Midatech Ltd in 2000 in England and Wales. It acquired its core nanoparticle technology and joint ownership of patent rights from Consejo Superior de Investigaciones Cientificas in Madrid, Spain. Midatech Ltd focused on research and development, advancing a gold nanoparticle drug delivery platform to improve medicine delivery for major therapeutic conditions with limited clinical options, specifically targeting certain cancers like liver and brain cancer. To further commercial development, Midatech Pharma PLC was incorporated on September 12, 2014, in England and Wales, serving as the public holding company for Midatech Ltd and Midatech Pharma (Wales) Limited. The company completed its initial public offering of Ordinary Shares in the United Kingdom on December 8, 2014. On December 4, 2015, it acquired DARA Biosciences, Inc., and subsequently listed its Depositary Shares on the NASDAQ Capital Market. On March 24, 2023, shareholders approved a name change to "Biodexa Pharmaceuticals PLC" and the cancellation of Ordinary Shares from trading on AIM, effective April 26, 2023. Midatech Ltd and Midatech Pharma (Wales) Limited were also renamed Biodexa Ltd and Biodexa Pharmaceuticals (Wales) Ltd, respectively. The principal executive and registered offices are in Cardiff, United Kingdom.